$24.580
+0.614 (+2.50%)收盤時
CBLL 資訊
CBLL 事件
Company Updates Outlook, Expects Revenue Growth of 28%-31%
Consensus $114M. The updated outlook represents growth of approximately 28% to 31% over the company's prior year revenue. This reflects continued momentum in its core business, driven by both new account additions and increased utilization within its established account base. "Combined with the early progress of our delirium pilot and multiple new FDA 510(k) clearances, we are highly confident in the strength of our business and our mission to establish EEG as a new vital sign," said CEO Jane Chao.
Company Reports Q2 Revenue of $28.1M, Beating Expectations
Reports Q2 revenue $28.1M, consensus $27.28M. Total revenue increased 33% year-over-year, driven primarily by continued growth in new account additions and increased utilization within existing accounts. "Our second quarter results reflect adoption accelerating across both new and existing accounts," said co-founder and CEO Jane Chao.
Ceribell Sees FY26 Revenue of $112M-$116M
Ceribell sees FY26 revenue $112M-$116M, consensus $113.18M
Company Reports Q1 Revenue of $26.5M, Exceeding Expectations
Reports Q1 revenue $26.5M, consensus $26.09M. "Our strong first quarter performance reflects solid execution against our commercial plan and the clear and growing demand for our seizure monitoring platform," said co-founder and CEO Jane Chao, Ph.D. "The launch of our neonate and pediatric offerings represents a major milestone in our commitment to provide critical brain monitoring for patients of all ages. As we work to redefine the standard of care in seizure management, we will continue to invest in innovation and expansion of our clinical indications to advance our mission to make EEG a new vital sign."
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。